bWell-D Pilot Randomized Controlled Trial (NCT06546917)
The bWell Cognitive Care Platform: A Pilot Feasibility Study in Patients With Depression
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to determine the acceptability, feasibility, and validity of the bWell Cognitive Care Platform for Depression (bWell-D), a novel Virtual Reality (VR) cognitive assessment and remediation tool, in depressed populations. The main questions are: * Do patients with Major Depressive Disorder (MDD) find the bWell-D cognitive assessment battery and protocol feasible, tolerable, and acceptable? * Do patients with Major Depressive Disorder (MDD) find the 8 week bWell-D remediation protocol feasible, tolerable, and acceptable? Following initial cognitive assessment, researchers will assess feasibility outcomes in the bWell remediation arm to a VR scenes experience arm to learn more about the feasibility of bWell for cognitive assessment and remediation. Patients will: * Complete an initial bWell cognitive assessment session * Randomized to either receive bWell cognitive remediation or a VR scenes experience twice a week for eight weeks * Complete cognitive/functional/clinical assessments and EEG at baseline, midpoint and endpoint of the remediation protocol, as well as two MRI scans and measures of tolerability, engagement, and enjoyment
Who can join: Review the eligibility criteria below.
Location: UBC Centre for Brain Health — Vancouver, British Columbia
Age range: 19 Years to 55 Years
🧪 Interventions in This Study
- bWell Cognitive Remediation (BEHAVIORAL)
- VR Experience (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- UBC Centre for Brain Health — Vancouver, British Columbia
📞 Contact the Study Coordinator
Phone: (604) 822-7512
Email: trisha.chakrabarty@ubc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Depressive Disorder, Major
- Psilocybin for Major Depressive Disorder (MDD) — Birmingham, Alabama
- A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder — Birmingham, Alabama
- Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Boston, Massachusetts
- Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Belmont, Massachusetts
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — Birmingham, Alabama
Explore by condition: All Depressive Disorder, Major clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.